 Anti-mitotic and anti-microtubule alkaloid
agent.
 Cell- cycle specific cytotoxic agents
 Produced synthetically.
 Vincristine
 Vinblastine
 Vinorelbine
 Vindesine
 INDICATIONS - Combination chemotherapy of
1. Lymphomas ( HL , NHL)
2. Advanced breast cancer
3. Non- seminomatous testicular carcinoma
 Cell cycle specific M phase action, binds to
proteins of mitotic spindle causing
metaphase arrest.
 Specific action- Inhibits angiogenesis
1. Death of rapidly replicating malignant cells.
2. Has immunosuppressive properties.
 CNS- Seizures, neurotoxicity, depression
 RESP- Bronchospasm
 GI- Nausea, Vomiting, Anorexia, Constipation
 DERM- Alopecia
 ENDO- SIADH
 HEMAT- Anemia, Leukopenia,Thrombocyopenia
 LOCAL- Phlebitis at IV site
 METAB- Hyperuricemia
 NEURO- Neuritis, peripheral neuropathy
 1mg/ml in 10 ml
vial
 Onset- 5-7 Days
 Peak- 10 days
 Duration- 7-14 Day
NURSING IMPLICATIONS
 Indications- used alone or in combination
with
1. HL
2. Leukemias
3. Neuroblastoma
4. Malignant melanoma
5. Rhabdomyosarcoma
6. Wilm’s tumour
1. CNS- Insomnia, Depression
2. EENT- Diplopia, Cortical blindness
3. RESP- Bronchospasm
4. GI- Nausea, Vomiting, Abdominal cramps,
Anorexia, Constipation, Stomatitis
5. GU-Gonadal suppression, Nocturia, Oliguria,
Urinary retention
6. Derm- Alopecia
7. Endo- SIADH
8. Hemat- Anemia, Leukopenia, Thrombocytopenia
9. Local- Phlebitis at IV site
10. Neuro- Ascending peripheral neurapathy
 1mg/ml in 1-25 ml
vials
 ONSET- unknown
 PEAK- 4 days
 DURATION- 7 days
NURSING IMPLICATIONS
Vinca alkaloids

Vinca alkaloids

  • 2.
     Anti-mitotic andanti-microtubule alkaloid agent.  Cell- cycle specific cytotoxic agents  Produced synthetically.
  • 7.
     Vincristine  Vinblastine Vinorelbine  Vindesine
  • 8.
     INDICATIONS -Combination chemotherapy of 1. Lymphomas ( HL , NHL) 2. Advanced breast cancer 3. Non- seminomatous testicular carcinoma
  • 9.
     Cell cyclespecific M phase action, binds to proteins of mitotic spindle causing metaphase arrest.  Specific action- Inhibits angiogenesis
  • 10.
    1. Death ofrapidly replicating malignant cells. 2. Has immunosuppressive properties.
  • 11.
     CNS- Seizures,neurotoxicity, depression  RESP- Bronchospasm  GI- Nausea, Vomiting, Anorexia, Constipation  DERM- Alopecia  ENDO- SIADH  HEMAT- Anemia, Leukopenia,Thrombocyopenia  LOCAL- Phlebitis at IV site  METAB- Hyperuricemia  NEURO- Neuritis, peripheral neuropathy
  • 12.
     1mg/ml in10 ml vial
  • 13.
     Onset- 5-7Days  Peak- 10 days  Duration- 7-14 Day
  • 14.
  • 15.
     Indications- usedalone or in combination with 1. HL 2. Leukemias 3. Neuroblastoma 4. Malignant melanoma 5. Rhabdomyosarcoma 6. Wilm’s tumour
  • 16.
    1. CNS- Insomnia,Depression 2. EENT- Diplopia, Cortical blindness 3. RESP- Bronchospasm 4. GI- Nausea, Vomiting, Abdominal cramps, Anorexia, Constipation, Stomatitis 5. GU-Gonadal suppression, Nocturia, Oliguria, Urinary retention 6. Derm- Alopecia 7. Endo- SIADH 8. Hemat- Anemia, Leukopenia, Thrombocytopenia 9. Local- Phlebitis at IV site 10. Neuro- Ascending peripheral neurapathy
  • 17.
     1mg/ml in1-25 ml vials
  • 18.
     ONSET- unknown PEAK- 4 days  DURATION- 7 days
  • 19.